Regulation of presympathetic RVLM neurons by cannabinoids
大麻素对交感前 RVLM 神经元的调节
基本信息
- 批准号:7531673
- 负责人:
- 金额:$ 21.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:AbdomenAgonistAreaAutonomic nervous systemBlood PressureBrainBrain StemCannabinoidsCapsaicinCardiovascular PhysiologyCardiovascular systemCellsClinicalConditionConfocal MicroscopyDataDevelopmentEndocannabinoidsG-Protein-Coupled ReceptorsGTP-Binding ProteinsGlutamatesGoalsHypertensionImmunohistochemistryIn VitroKidneyLocalizedMeasuresMediatingMedicalMicroinjectionsNerveNeuraxisNeuronsPathway interactionsPlayPublic HealthRattusReceptor ActivationReflex actionRegulationRenal functionResearch Project GrantsRoleSiteSpinal CordSympathetic Nervous SystemSynapsesTestingVanilloidVasomotoranandamideblood pressure regulationcannabinoid receptorconcepthypertension treatmentin vivoinsightkidney medullanovel therapeuticspatch clampreceptorresearch studyresponse
项目摘要
DESCRIPTION (provided by applicant): The overall goal of this Exploratory/Developmental Research Grant is to discover the effects of endocannabinoids (eCB) in rostral ventrolateral medulla (RVLM) circuits that regulate cardiovascular function. The central nervous system is directly involved in regulation of arterial blood pressure, largely through actions of the sympathetic nervous system on renal function and abdominal vasculature. The RVLM is a critical component in the central pathways mediating cardiovascular regulation. Presympathetic RVLM neurons receive inputs from multiple areas of the brain and spinal cord, and mediate many cardiovascular reflexes. Hypertension may result from an imbalance between activity of sympathetic vasomotor neurons and those cells that inhibit them. This concept has been described as the "central neuron imbalance" hypothesis of hypertension. Little is known about normal RVLM neuronal regulation. The G protein-coupled cannabinoid type-1 receptor (CB1R) is expressed throughout the CNS, including the RVLM. Endogenous cannabinoids (eCB), (e. g. anandamide), act on both CB1R and transient receptor potential vanilloid type 1 (TRPV1), which are also expressed in the RVLM. The function of CB1R and TRPV1 receptors in RVLM is not known. This exploratory study will reveal the site and synaptic mechanisms of eCB actions in RVLM-mediated cardiovascular control, which have been elusive until now. A multi-disciplinary approach using immunohistochemistry, in vivo renal nerve and arterial blood pressure (ABP) recordings and in vitro patch-clamp recordings of synaptic currents in identified RVLM neurons to test the hypothesis that: 1) CB1R agonists will evoke sympathoexcitation when injected into the RVLM of anesthetized rats by decreasing GABAergic synaptic activity to presympathetic RVLM kidney-related neurons. 2) TRPV1 agonists will evoke sympathoinhibition when injected into the RVLM of anesthetized rats. Exploring these mechanisms will provide important insights about understanding the cellular mechanisms of cannabinoid actions on RVLM. This approach will also have clinical implications by providing direct evidence about the regulation of ABP by cannabinoids and therefore offer novel therapeutic strategies in the treatment of hypertension. PUBLIC HEALTH RELEVANCE: This study will reveal the site and effect of cannabinoids on a brainstem area involved in blood pressure control. Cannabinoid actions in the brainstem can have important clinical implications for the treatment of such medical conditions as hypertension.
描述(由申请人提供):这项探索性/发展性研究资助的总体目标是发现内源性大麻素(eCB)在延髓头端腹外侧(RVLM)回路中调节心血管功能的作用。中枢神经系统直接参与动脉血压的调节,主要通过交感神经系统对肾功能和腹部血管系统的作用。RVLM是介导心血管调节的中枢通路中的关键组分。前交感RVLM神经元从大脑和脊髓的多个区域接收输入,并介导许多心血管反射。高血压可能是由于交感血管神经元和抑制交感血管神经元的细胞之间的活动不平衡造成的。这一概念被描述为高血压的“中枢神经元失衡”假说。关于正常RVLM神经元调节知之甚少。G蛋白偶联大麻素1型受体(CB 1 R)在整个CNS中表达,包括RVLM。内源性大麻素(eCB),(e. G.大麻素(anandamide)作用于CB 1 R和瞬时受体电位香草素1型(TRPV 1),其也在RVLM中表达。CB 1 R和TRPV 1受体在RVLM中的功能尚不清楚。这项探索性研究将揭示RVLM介导的心血管控制中eCB作用的位点和突触机制,这一点迄今为止一直是难以捉摸的。采用免疫组织化学、体内肾神经和动脉血压(ABP)记录以及已鉴定RVLM神经元中突触电流的体外膜片钳记录的多学科方法来检验以下假设:1)CB 1 R激动剂注射到麻醉大鼠的RVLM中时,通过降低对前交感RVLM肾相关神经元的GABA能突触活性,引起交感兴奋。2)TRPV 1激动剂注射到麻醉大鼠的RVLM时会引起交感神经抑制。探索这些机制将为理解大麻素对RVLM作用的细胞机制提供重要的见解。这种方法也将通过提供大麻素调节ABP的直接证据而具有临床意义,因此为高血压的治疗提供了新的治疗策略。公共卫生相关性:这项研究将揭示大麻素对涉及血压控制的脑干区域的部位和作用。脑干中的大麻素作用对于治疗高血压等疾病具有重要的临床意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrei Derbenev其他文献
Andrei Derbenev的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrei Derbenev', 18)}}的其他基金
Brain Circuits Involved in the Sympathetic Control of the Liver
参与肝脏交感神经控制的脑回路
- 批准号:
10379952 - 财政年份:2020
- 资助金额:
$ 21.98万 - 项目类别:
Brain Circuits Involved in the Sympathetic Control of the Liver
参与肝脏交感神经控制的脑回路
- 批准号:
10609018 - 财政年份:2020
- 资助金额:
$ 21.98万 - 项目类别:
Sympathetic control and hypertension via brainstem cannabinoid signaling
通过脑干大麻素信号传导的交感神经控制和高血压
- 批准号:
9124931 - 财政年份:2015
- 资助金额:
$ 21.98万 - 项目类别:
Sympathetic control and hypertension via brainstem cannabinoid signaling
通过脑干大麻素信号传导的交感神经控制和高血压
- 批准号:
8888884 - 财政年份:2015
- 资助金额:
$ 21.98万 - 项目类别:
Regulation of presympathetic RVLM neurons by cannabinoids
大麻素对交感前 RVLM 神经元的调节
- 批准号:
7929078 - 财政年份:2009
- 资助金额:
$ 21.98万 - 项目类别:
Regulation of presympathetic RVLM neurons by cannabinoids
大麻素对交感前 RVLM 神经元的调节
- 批准号:
7682070 - 财政年份:2008
- 资助金额:
$ 21.98万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 21.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 21.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 21.98万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 21.98万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 21.98万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 21.98万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 21.98万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 21.98万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 21.98万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 21.98万 - 项目类别:














{{item.name}}会员




